ENV 201
Alternative Names: ENV-201; ENV-ONC-201Latest Information Update: 05 Dec 2022
At a glance
- Originator Salk Institute; Sanford Burnham Prebys Medical Discovery Institute
- Developer Endeavor BioMedicines
- Class Antineoplastics; Small molecules
- Mechanism of Action Ulk2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Lung cancer
Most Recent Events
- 05 Dec 2022 3735466 - KDM, Pharmacodynamic data and HE added
- 05 Dec 2022 Pharmacodynamics data from preclinical trial in Non-small cell lung cancer presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics(EORTC-NCI-AACR-2022)
- 18 Feb 2022 Endeavor BioMedicines plans to complete IND-enabling studies and initiate clinic trials for Colorectal cancer and Lung cancer in 2023